NCT04442945

Phase 1 Study of ANAVEX3-71

A Double-blind, Randomized, Placebo-controlled, Phase 1 Safety and Tolerability, and Pharmacokinetics Study of ANAVEX3-71

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Anavex Life Sciences Corp. · Industry
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

A first in human phase 1 study in healthy volunteers to assess ANAVEX3-71 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Detailed description

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and bioavailability of orally administered ANAVEX3-71 in healthy volunteers

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ANAVEX3-71	Active oral dose of ANAVEX3-71
DRUG	Placebo	Oral placebo

Timeline

• Start date: 2020-07-03
• Primary completion: 2021-09-30
• Completion: 2021-10-30
• First posted: 2020-06-23
• Last updated: 2022-01-19

Locations

1 site across 1 country: Australia